Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NYSE American - Delayed Quote USD

Oragenics, Inc. (OGEN)

Compare
0.2123
+0.0023
+(1.10%)
At close: April 1 at 4:00:00 PM EDT
0.2098
-0.00
(-1.18%)
After hours: April 1 at 7:49:21 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
10,558.8150
10,558.8150
--
14,420.7680
15,772.3750
Operating Income
-10,558.8150
-10,558.8150
--
-14,420.7680
-15,772.3750
Net Non Operating Interest Income Expense
16.0690
16.0690
--
120.7970
60.0910
Other Income Expense
-25.1720
-25.1720
--
11.5820
0.6700
Pretax Income
-10,567.9180
-10,567.9180
--
-14,288.3890
-15,711.6140
Net Income Common Stockholders
-10,567.9180
-10,567.9180
--
-14,288.3890
-15,711.6140
Diluted NI Available to Com Stockholders
-10,567.9180
-10,567.9180
--
-14,288.3890
-15,711.6140
Basic EPS
-6.97
-1.60
-9.18
-7.11
-8.09
Diluted EPS
-6.97
-1.60
-9.18
-7.11
-8.09
Basic Average Shares
4,290.3260
6,621.9340
2,249.6940
2,009.2340
1,943.1300
Diluted Average Shares
4,290.3260
6,621.9340
2,249.6940
2,009.2340
1,943.1300
Total Operating Income as Reported
-10,558.8150
-10,558.8150
--
-14,420.7680
-15,771.0180
Total Expenses
10,558.8150
10,558.8150
--
14,420.7680
15,772.3750
Net Income from Continuing & Discontinued Operation
-10,567.9180
-10,567.9180
--
-14,288.3890
-15,711.6140
Normalized Income
-10,542.7460
-10,542.7460
--
-14,288.3890
-15,711.6140
Interest Income
45.8970
45.8970
--
135.9000
75.8470
Interest Expense
29.8280
29.8280
--
15.1030
15.7560
Net Interest Income
16.0690
16.0690
--
120.7970
60.0910
EBIT
-10,538.0900
-10,538.0900
--
-14,273.2860
-15,695.8580
EBITDA
-10,538.0900
-10,538.0900
--
-14,228.6190
-15,654.6210
Reconciled Depreciation
--
--
--
44.6670
41.2370
Net Income from Continuing Operation Net Minority Interest
-10,567.9180
-10,567.9180
--
-14,288.3890
-15,711.6140
Total Unusual Items Excluding Goodwill
-25.1720
-25.1720
--
--
--
Total Unusual Items
-25.1720
-25.1720
--
--
--
Normalized EBITDA
-10,512.9180
-10,512.9180
--
-14,228.6190
-15,654.6210
12/31/2021 - 2/25/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AZTR Azitra, Inc.
0.2900
-4.29%
 
HCWB HCW Biologics Inc.
0.2809
-0.43%
 
ENTO Entero Therapeutics, Inc.
0.4101
-14.58%
 
INAB IN8bio, Inc.
0.1727
+4.04%
 
TCBPY TC Biopharm (Holdings) Plc
0.3200
+52.38%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.2116
-7.68%
 
APTO Aptose Biosciences Inc.
1.7100
-45.97%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
1.8900
+5.00%
 
SCPX Scorpius Holdings, Inc.
0.1282
-7.77%
 
RLMD Relmada Therapeutics, Inc.
0.2736
+1.33%